Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia
作者: Irina ProskorovskyYun SuKyle FahrbachErik VandendriesVéronique PagéUchenna OnyekwereYunyang WangJoseph C. CappelleriMatthias Stelljes
作者单位: 1Evidera
2Pfizer Inc
3University Hospital
刊名: Advances in Therapy, 2019, Vol.36 (8), pp.2147-2160
来源数据库: Springer Journal
DOI: 10.1007/s12325-019-00991-w
关键词: BlinatumomabIndirect treatment comparisonInotuzumab ozogamicinMatching-adjusted indirect comparisonRelapsed or refractory acute lymphoblastic leukemiaSimulated treatment comparison
英文摘要: Abstract(#br) Introduction(#br)No head-to-head studies have compared inotuzumab ozogamicin (InO) and blinatumomab (Blina) for the treatment of adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL). Indirect treatment comparisons (ITCs), namely network meta-analysis (NMA), anchored matching-adjusted indirect comparison (MAIC), and simulated treatment comparison (STC), were conducted to compare the relative efficacy of these therapies.(#br) Methods(#br)Patient-level data from a study that evaluated InO with standard of care (SoC) chemotherapy (INO-VATE-ALL) and published data from a study that evaluated Blina with SoC chemotherapy (TOWER) were used in the analyses. Endpoints evaluated included remission rate defined as complete remission or complete...
全文获取路径: Springer  (合作)
分享到:
来源刊物:
影响因子:2.125 (2012)

×